HuGE Literature Finder
Records
1
-
30
| The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients. Genomics & informatics 2022 Sep 20 (3): e29. Lee Choong-Kun, Chon Hong Jae, Kwon Woo Sun, Ban Hyo-Jeong, Kim Sang Cheol, Kim Hyunwook, Jeung Hei-Cheul, Chung Jimyung, Rha Sun You |
| Potentially functional genetic variants in PLIN2, SULT2A1 and UGT1A9 genes of the ketone pathway and survival of nonsmall cell lung cancer. International journal of cancer 2020 Feb . Tang Dongfang, Zhao Yu Chen, Liu Hongliang, Luo Sheng, Clarke Jeffrey M, Glass Carolyn, Su Li, Shen Sipeng, Christiani David C, Gao Wen, Wei Qing |
| Effect of UGT, SLCO, ABCB and ABCC polymorphisms on irinotecan toxicity. Medicina clinica 2018 Feb . García Gil Sara, Ramos Díaz Ruth, Nazco Casariego Gloria Julia, Llanos Muñoz Marta, Viña Romero Maria Micaela, Martín Calero Braulio, Pérez Pérez Jose Antonio, Gutiérrez Nicolás Fernan |
| Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis. BMC cancer 2017 Jun 17 (1): 437. Liu Dan, Li Jian, Gao Jing, Li Yanyan, Yang Rui, Shen L |
| UGT1A1*6, UGT1A7*3 and UGT1A9*1b polymorphisms are predictive markers for severe toxicity in patients with metastatic gastrointestinal cancer treated with irinotecan-based regimens. Oncology letters 2016 Nov 12 (5): 4231-4237. Cui Chengxu, Shu Chang, Cao Dandan, Yang Yi, Liu Junbao, Shi Shuping, Shao Zhujun, Wang Nan, Yang Ting, Liang Hao, Zou Shanshan, Hu Songni |
| Variations of chromosome 2 gene expressions among patients with lung cancer or non-cancer. Cell biology and toxicology 2016 Jun . Bao Lianmin, Zhang Yong, Wang Jian, Wang Haiyun, Dong Nian, Su Xiaoqiong, Xu Menglin, Wang Xiangdo |
| Bisphenol-A glucuronidation in human liver and breast: identification of UDP-glucuronosyltransferases (UGTs) and influence of genetic polymorphisms. Xenobiotica; the fate of foreign compounds in biological systems 2016 Mar 1-10. Street Christina M, Zhu Zhaohui, Finel Moshe, Court Michael |
| Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity. Pharmacogenomics 2016 09 17 (14): 1483-90. Bins Sander, Lenting Anne, El Bouazzaoui Samira, van Doorn Leni, Oomen-de Hoop Esther, Eskens Ferry Alm, van Schaik Ron Hn, Mathijssen Ron |
| The UGT1 locus is a determinant of prostate cancer recurrence after prostatectomy. Endocrine-related cancer 2015 Feb 22 (1): 77-85. Laverdière Isabelle, Flageole Christine, Audet-Walsh Étienne, Caron Patrick, Fradet Yves, Lacombe Louis, Lévesque Éric, Guillemette Chant |
| UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2015 Jan 24 (1): 94-104. Wassenaar Catherine A, Conti David V, Das Soma, Chen Peixian, Cook Edwin H, Ratain Mark J, Benowitz Neal L, Tyndale Rachel |
| A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes. International journal of oncology 2014 Oct 45 (4): 1381-90. Tsunedomi Ryouichi, Hazama Shoichi, Fujita Yusuke, Okayama Naoko, Kanekiyo Shinsuke, Inoue Yuka, Yoshino Shigefumi, Yamasaki Takahiro, Suehiro Yutaka, Oba Koji, Mishima Hideyuki, Sakamoto Junichi, Hamamoto Yoshihiko, Oka Masaa |
| XELIRI compared with FOLFIRI as a second-line treatment in patients with metastatic colorectal cancer. Oncology letters 2014 Oct 8 (4): 1864-1872. Cui Chengxu, Shu Chang, Yang Yi, Liu Junbao, Shi Shuping, Shao Zhujun, Wang Nan, Yang Ting, Hu Songni |
| UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. Cancer science 2013 Dec 104 (12): 1662-9. Hazama Shoichi, Mishima Hideyuki, Tsunedomi Ryouichi, Okuyama Yusuke, Kato Takeshi, Takahashi Ken-ichi, Nozawa Hiroshi, Ando Hideaki, Kobayashi Michiya, Takemoto Hiroyoshi, Nagata Naoki, Kanekiyo Shinsuke, Inoue Yuka, Hamamoto Yoshihiko, Fujita Yusuke, Hinoda Yuji, Okayama Naoko, Oba Koji, Sakamoto Jun-ichi, Oka Masaa |
| Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer 2013 Jan 119 (1): 136-42. Lee Joo Ho, Chung Young-Hwa, Kim Jeong A, Shim Ju Hyun, Lee Danbi, Lee Han Chu, Shin Eun-Soon, Yoon Jung Hwan, Kim Byung Ik, Bae Si Hyun, Koh Kwang Cheol, Park Neung-H |
| Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy. The Tohoku journal of experimental medicine 2013 229 (2): 107-14. Inoue Kazuyuki, Sonobe Momoyo, Kawamura Yukinori, Etoh Takashi, Takagi Masakazu, Matsumura Takashi, Kikuyama Masataka, Kimura Midori, Minami Sato, Utsuki Hiroaki, Yamazaki Tomoaki, Suzuki Takayo, Tsuji Daiki, Hayashi Hideki, Itoh Kunihi |
| Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Feb . Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel JD, Venzon D, Dahut B, Kohn EC, Kummar S, Yarchoan R, Giaccone G, Widemann BC, Figg WD |
| Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study. PloS one 2012 7 (8): e42875. Boudou-Rouquette Pascaline, Narjoz Céline, Golmard Jean Louis, Thomas-Schoemann Audrey, Mir Olivier, Taieb Fabrice, Durand Jean-Philippe, Coriat Romain, Dauphin Alain, Vidal Michel, Tod Michel, Loriot Marie-Anne, Goldwasser François, Blanchet Beno |
| Polymorphisms in heterocyclic aromatic amines metabolism-related genes are associated with colorectal adenoma risk. International journal of molecular epidemiology and genetics 2012 3 (2): 96-106. Eichholzer Monika, Rohrmann Sabine, Barbir Aline, Hermann Silke, Teucher Birgit, Kaaks Rudolf, Linseisen Jak |
| UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. British journal of cancer 2010 Aug 103 (4): 581-9. Martinez-Balibrea E, Abad A, Martínez-Cardús A, Ginés A, Valladares M, Navarro M, Aranda E, Marcuello E, Benavides M, Massutí B, Carrato A, Layos L, Manzano J L, Moreno |
| Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PloS one 2010 5 (11): e13792. Ni Wenjun, Ji Jia, Dai Zunyan, Papp Audrey, Johnson Amy J, Ahn Sunjoo, Farley Katherine L, Lin Thomas S, Dalton James T, Li Xiaobai, Jarjoura David, Byrd John C, Sadee Wolfgang, Grever Michael R, Phelps Mitch |
| Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 May 27 (15): 2457-65. Cecchin Erika, Innocenti Federico, D'Andrea Mario, Corona Giuseppe, De Mattia Elena, Biason Paola, Buonadonna Angela, Toffoli Giusep |
| Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese. Drug metabolism and disposition: the biological fate of chemicals 2009 Feb 37 (2): 272-6. Saito Yoshiro, Sai Kimie, Maekawa Keiko, Kaniwa Nahoko, Shirao Kuniaki, Hamaguchi Tetsuya, Yamamoto Noboru, Kunitoh Hideo, Ohe Yuichiro, Yamada Yasuhide, Tamura Tomohide, Yoshida Teruhiko, Minami Hironobu, Ohtsu Atsushi, Matsumura Yasuhiro, Saijo Nagahiro, Sawada Jun-Ic |
| Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Therapeutic drug monitoring 2008 Oct 30 (5): 559-64. Miura Masatomo, Kagaya Hideaki, Satoh Shigeru, Inoue Kazuyuki, Saito Mitsuru, Habuchi Tomonori, Suzuki Tosh |
| UGT1A1 and UGT1A9 functional variants, meat intake, and colon cancer, among Caucasians and African-Americans. Mutation research 2008 Sep 644 (1-2): 56-63. Girard Hugo, Butler Lesley M, Villeneuve Lyne, Millikan Robert C, Sinha Rashmi, Sandler Robert S, Guillemette Chant |
| Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients. The pharmacogenomics journal 2008 Jun 8 (3): 174-85. Sandanaraj E, Jada S R, Shu X, Lim R, Lee S C, Zhou Q, Zhou S, Goh B C, Chowbay |
| Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer chemotherapy and pharmacology 2007 Sep 60 (4): 515-22. Fujita Ken-ichi, Ando Yuichi, Nagashima Fumio, Yamamoto Wataru, Eodo Hisashi, Araki Kazuhiro, Kodama Keiji, Miya Toshimichi, Narabayashi Masaru, Sasaki Yasutsu |
| Lack of association between UGT1A7, UGT1A9, ARP, SPINK1 and CFTR gene polymorphisms and pancreatic cancer in Italian patients. World journal of gastroenterology : WJG 2006 Oct 12 (39): 6343-8. Piepoli Ada, Gentile Annamaria, Valvano Maria Rosa, Barana Daniela, Oliani Cristina, Cotugno Rosa, Quitadamo Michele, Andriulli Angelo, Perri Frances |
| Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006 May 24 (15): 2237-44. Han Ji-Youn, Lim Hyeong-Seok, Shin Eun Soon, Yoo Yeon-Kyeong, Park Yong Hoon, Lee Jong-Eun, Jang In-Jin, Lee Dae Ho, Lee Jin S |
| UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Feb 11 (3): 1226-36. Carlini Leslie E, Meropol Neal J, Bever John, Andria Michael L, Hill Todd, Gold Philip, Rogatko Andre, Wang Hao, Blanchard Rebecca |
| [Influence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokynetics of irinotecan, SN-38 and SN-38G]. Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria 0 37 (2): 111-27. Valenzuela Jiménez B, González Sales M, Escudero Ortiz V, Martínez Navarro E, Pérez Ruixo C, Rebollo Liceaga J, González Manzano R, Pérez Ruixo J |
- Page last reviewed:Jul 25, 2022
- Page last updated:Dec 08, 2022
- Content source: